Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

CERo Therapeutics Holdings, Inc. (CERO)

OQB · Biotechnology

$0.01+0.00 (+27.84%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$559,393
P/E (TTM)
0.00
EPS
$11.56
Div Yield
52W Range
$0.01–$8.90
Beta
0.16

Company overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

8 employeeswww.cero.bio

Peers in Healthcare

CERo Therapeutics Holdings, Inc. has no peer companies in this window.

Recent press releases

CERo Therapeutics Holdings, Inc. has not issued a press release in this window.

SEC filings

All filings →

CERo Therapeutics Holdings, Inc. has not filed an SEC document in this window.

CERo Therapeutics Holdings, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →

No 13F holdings have been reported for CERo Therapeutics Holdings, Inc. in this window.

People at CERo Therapeutics Holdings, Inc.

All people →

Quarterly financials

Full financials →

No quarterly financials have been ingested for CERo Therapeutics Holdings, Inc..

CERO (OQB) Stock Quote, Press Releases & SEC... | Cayman Journal | Cayman Journal